Zhi Tong Cai Jing·2026-03-06 02:32Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profitability for the fiscal year 2025, driven by higher sales of its injectable products and a substantial rise in technology licensing income [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share were RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales of injectable drugs, specifically Tai Tasi Pi and Vidi Si Tuo Monoclonal Antibody [1] - The company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tai Tasi Pi outside Greater China, leading to a significant increase in technology licensing income [1] Margin and Expenditure Outlook - Nomura's research report predicts that the company's gross margin will increase by 5.4 percentage points year-on-year to 94.4%, benefiting from improved drug margins and a higher proportion of high-margin collaborative income [1] - Operating expenses are expected to rise by 28% year-on-year to RMB 3.5 billion due to a significant increase in cash reserves, reversing last year's cost-saving trend [1] - Research and development expenses and sales costs are projected to be RMB 1.6 billion each, aimed at sponsoring new molecular research and clinical trials, as well as enhancing drug sales [1]